Jaklenec Group's News

June 11, 2024

Award-winning KI Images creators Jooli Han and Linzixuan (Rhoda) Zhang present on their image, "The Golden Monument: New Heights for Global Health." Jaklenec and Langer Lab technologies can administer multiple vaccine doses with a...

June 3, 2024

The Jaklenec Group attended the first-ever AIMBE Regional Event hosted by Boston University! Local fellows showcased innovations from BU, Harvard, MIT, Northeastern, and Tufts. Dr. Ana Jaklenec and P.h.D. student, Rhoda Zhang, presented new possibilities and equity...

March 8, 2024

Numerous vaccines, such as those for whooping cough and hepatitis B, contain bits of bacterial or viral proteins. These vaccines also often contain adjuvants, which are molecules that help enhance the response of the immune system to the...

March 8, 2024

Researchers from the Massachusetts Institute of Technology (MIT) have revealed that a new type of nanoparticle could be used to improve the delivery and immune responses of vaccines...

March 7, 2024

In a landmark breakthrough, scientists at the Massachusetts Institute of Technology have unveiled a pioneering approach to vaccine development with the potential to reshape the landscape of preventive medicine...

March 7, 2024

Zeolitic imidazolate frameworks boost SARS-CoV-2 spike protein trimer immunity via Toll-like receptor activation...

March 6, 2024

Study shows metal-organic particles can both deliver vaccines and act as an adjuvant to generate a strong immune response at a lower dose...

March 6, 2024

Vaccines are one of the best scientific discoveries because they prevent the incidence of some of the deadliest diseases. The medical field has been using them to prevent smallpox, tuberculosis, and even cancer. A recent study...

March 6, 2024

In the heart of Cambridge, Massachusetts, a groundbreaking discovery has emerged from the laboratories of the Massachusetts Institute of Technology (MIT). A team of scientists, driven by curiosity and an unyielding commitment to public health, has unlocked a new...

March 6, 2024

Nanomaterials offer unique opportunities to engineer immunomodulatory activity. In this work, we report the Toll-like receptor agonist activity of a nanoscale adjuvant zeolitic imidazolate framework–8 (ZIF-8)...